Month: May 2023

– Continued Commercial Momentum Within Core Cannabinoid Markets – – Recent Commercial Launches of Colombian Dry Flower Exports to Australia and Germany Mark Key Operational Milestone – – Continuing Cost Reduction Measures Drive Leaner Operational Infrastructure – – Reiterating Previously Issued 2023 Outlook – TOCANCIPÁ, Colombia, May 11, 2023 (GLOBE NEWSWIRE) — Clever Leaves Holdings Inc. (NASDAQ: CLVR, CLVRW) (“Clever Leaves” or the “Company”), a global medicinal cannabis company, is reporting financial and operating results for the first quarter ended March 31, 2023. All financial information is provided in US dollars unless otherwise indicated. “Our first quarter performance reflects the progress we are making on our key growth objectives, including our focused commercial strategy,...

First Quarter Revenues Increased 17% to $42.1 millionFirst Quarter Gross Margin Expanded to 54% First Quarter Net Loss Attributable to UpHealth, Inc. Decreased 54% to $8.1 millionFirst Quarter Adjusted EBITDA Improved by $7.9 million to $6.6 million Announced Strategic Sale of Innovations Group, Inc. for $56.0 million DELRAY BEACH, Fla., May 11, 2023 (GLOBE NEWSWIRE) — UpHealth, Inc. (“UpHealth” or the “Company”) (NYSE: UPH), a global digital health company delivering technology platforms, infrastructure, and services to modernize care delivery and health management, today announced financial results for the first quarter ended March 31, 2023. UpHealth Chief Executive Officer Sam Meckey said, “I am very proud of our team’s efforts which contributed to our top line growth of 17% to $42.1 million in the first quarter of 2023 over...

NEW YORK, May 11, 2023 (GLOBE NEWSWIRE) — Getty Images Holdings, Inc. (“Getty Images” or the “Company”) (NYSE: GETY), a preeminent global visual content creator and marketplace, today reported financial results for the first quarter ended March 31, 2023. “We are pleased to report a quarter of revenue growth, all of which is organic, despite foreign exchange pressures, driven by strong subscription growth, subscription renewal rates, new customer growth and increased consumption of our content,” said Craig Peters, Chief Executive Officer of Getty Images. “The increased customer commitment and consumption is underpinned by the uniqueness and quality of our content offerings. We are focused on expanding this differentiation alongside embracing new capabilities to increase the value we provide to our customers and create new and recurring...

Conference Call on Thursday, May 11, 2023, at 9 p.m. ET with Accompanying Investor Presentation BEIJING, May 11, 2023 (GLOBE NEWSWIRE) — ATA Creativity Global (“ACG” or the “Company”, Nasdaq: AACG), an international educational services company focused on providing quality learning experiences that cultivate and enhance students’ creativity, today announced preliminary unaudited financial results for the quarter ended March 31, 2023 (“First Quarter 2023”). First Quarter 2023 HighlightsDuring First Quarter 2023, student enrollment was 1,097, an increase of 10.0% from 997 in the prior-year period. Excluding the 171 enrollments from the foreign language training business ACG disposed of in Third Quarter 2022, student enrollment increased by 271 compared to the prior-year period. Of the 1,097 students, 648 were enrolled in ACG’s...

SHAKOPEE, Minn., May 11, 2023 (GLOBE NEWSWIRE) — Canterbury Park Holding Corporation (“Canterbury” or the “Company”) (NASDAQ: CPHC), today reported financial results for the first quarter ended March 31, 2023.($ in thousands, except per share data and percentages)  Three Months Ended March 31,   2023    2022   ChangeNet revenues $13,300   $13,638   -2.5%           Net income   $2,771   $1,774   56.2%           Adjusted EBITDA (1) $2,482   $3,547   -30.0%           Basic EPS $0.57   $0.37   53.8%Diluted EPS $0.56   $0.36   54.2%(1) Adjusted EBITDA, a non-GAAP measure, excludes certain items from net income, a GAAP measure. Non-GAAP financial measures are not intended to be considered in isolation from, a substitute for, or superior to GAAP results. Definitions, disclosures, and reconciliations...

First patient dosed in global Phase 2b clinical trial of lead oral IL-17 inhibitor, DC-806, in moderate-to-severe psoriasis Topline data from Phase 1 clinical trial of second oral IL-17 inhibitor, DC-853, in healthy volunteers expected in 2H 2023 Strong financial position with $554.5 million in cash, cash equivalents and marketable securities, providing runway into 2026 and through multiple expected clinical milestonesSOUTH SAN FRANCISCO, Calif., May 11, 2023 (GLOBE NEWSWIRE) — DICE Therapeutics, Inc. (Nasdaq: DICE) (DICE or the Company), a biopharmaceutical company leveraging its proprietary DELSCAPE technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology, today reported financial results for the first quarter ended March 31, 2023, and highlighted recent corporate...

– On Track to Report Initial Clinical Data from pheEDIT PKU Gene Editing Trial Mid-Year 2023 – – First Presentations of Preclinical Data with GTx-mAb Development Candidate HMI-104 for PNH, and Potential for Re-Dosing with AAVHSCs, at Upcoming ASGCT Meeting – – Solid Financial Position with Anticipated Cash Runway into Fourth Quarter 2024 – BEDFORD, Mass., May 11, 2023 (GLOBE NEWSWIRE) — Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today financial results for the first quarter ended March 31, 2023, and highlighted recent accomplishments. “We look forward to announcing the first gene editing data in people with PKU, as we are on track to report initial clinical data mid-year 2023 from our pheEDIT trial evaluating HMI-103,” said Albert Seymour, Ph.D., President...

PORTLAND, Maine, May 11, 2023 (GLOBE NEWSWIRE) — ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced its unaudited financial results for the quarter ended March 31, 2023. Management’s Discussion:“Our unaudited, preliminary product sales were first reported on April 5, 2023,” commented Michael F. Brigham, President and CEO of ImmuCell. “We have no changes to those figures.” “We have just persevered through the most difficult quarter in the history of the Company,” continued Mr. Brigham. “As previously disclosed, we made the strategic decision to significantly reduce production output to remediate a production contamination...